# An Investigation of the Pharmacokinetics of GSK961081 and Fluticasone Propionate in Healthy Volunteers

> **NCT01449799** · PHASE1 · COMPLETED · sponsor: **GlaxoSmithKline** · enrollment: 24 (actual)

## Conditions studied

- Pulmonary Disease, Chronic Obstructive

## Interventions

- **DRUG:** GSK961081 800 microgram dose
- **DRUG:** Fluticasone Propionate 500 microgram dose
- **DRUG:** GSK961081 800 microgram and Fluticasone Propionate 500 microgram separately
- **DRUG:** GSK961081 800 microgram Fluticasone Propionate 500 microgram in a blend

## Key facts

- **NCT ID:** NCT01449799
- **Lead sponsor:** GlaxoSmithKline
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2011-07-13
- **Primary completion:** 2011-09-21
- **Final completion:** 2011-09-21
- **Target enrollment:** 24 (ACTUAL)
- **Last updated:** 2017-07-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01449799

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01449799, "An Investigation of the Pharmacokinetics of GSK961081 and Fluticasone Propionate in Healthy Volunteers". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT01449799. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*